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Abstract
Aims/hypothesis It is unclear whether type 1 diabetes is a single disease or if endotypes exist. Our aim was to use a unique
collection of pancreas samples recovered soon after disease onset to resolve this issue.
Methods Immunohistological analysis was used to determine the distribution of proinsulin and insulin in the islets of pancreas
samples recovered soon after type 1 diabetes onset (<2 years) from young people diagnosed at age <7 years, 7–12 years and
≥13 years. The patterns were correlated with the insulitis profiles in the inflamed islets of the same groups of individuals. C-
peptide levels and the proinsulin:C-peptide ratio were measured in the circulation of a cohort of living patients with longer
duration of disease but who were diagnosed in these same age ranges.
Results Distinct patterns of proinsulin localisation were seen in the islets of people with recent-onset type 1 diabetes, which
differed markedly between children diagnosed at <7 years and those diagnosed at ≥13 years. Proinsulin processing was aberrant
in most residual insulin-containing islets of the younger group but this was much less evident in the group ≥13 years (p < 0.0001).
Among all individuals (including children in the middle [7–12 years] range) aberrant proinsulin processing correlated with the
assigned immune cell profiles defined by analysis of the lymphocyte composition of islet infiltrates. C-peptide levels were much
lower in individuals diagnosed at <7 years than in those diagnosed at ≥13 years (median <3 pmol/l, IQR <3 to <3 vs 34.5 pmol/l,
IQR <3–151; p < 0.0001), while the median proinsulin:C-peptide ratio was increased in those with age of onset <7 years
compared with people diagnosed aged ≥13 years (0.18, IQR 0.10–0.31) vs 0.01, IQR 0.009–0.10 pmol/l; p < 0.0001).
Conclusions/interpretation Among those with type 1 diabetes diagnosed under the age of 30 years, there are histologically
distinct endotypes that correlate with age at diagnosis. Recognition of such differences should inform the design of future
immunotherapeutic interventions designed to arrest disease progression.
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Introduction
Type 1 diabetes is an autoimmune disease caused by destruc-
tion of pancreatic beta cells leading to severe insulin deficien-
cy. Most attempts to prevent, slow or reverse the disease
process have been unsuccessful [1–3], although recent clinical
trials undertaken with the humanised anti-CD3 reagent
teplizumab suggest that targeted interventions can be effective
[4]. One obstacle to the development of still more effective
therapeutic approaches is a continuing incomplete understand-
ing of the aetiopathology of the disease at the level of the
pancreas. Therefore, to address this, we havemade use of both
the Network of Pancreatic Organ Donors (nPOD) biobank of
organ donor pancreas samples collected in the USA and a
separate, unique, collection of pancreases recovered from
young people close to the clinical onset of type 1 diabetes
from the UK [5, 6]. In particular, we have adopted a histolog-
ical approach to consider an important question raised by
emerging data (reviewed recently by Battaglia et al [7]) which
imply that type 1 diabetes may not represent a single disease
but that distinct endotypes exist. This concept is of critical
importance since, if verified, it suggests that different immu-
notherapeutic approaches will be required to achieve success-
ful intervention in specific groups of patients.
Previously, we described the existence of two discrete
histological profiles of pancreatic insulitis that associate
strongly with age at diagnosis of type 1 diabetes [8, 9]. In
principle, these data are consistent with the existence of
disease endotypes but such a conclusionmust be substantiated
by the assessment of additional variables. Therefore, we have
now adopted an entirely independent approach to evaluate
more fully whether disease endotypes can be distinguished
at the level of the human pancreas. To achieve this, we have
studied the processing of proinsulin in the islets of children
and young people with recent-onset type 1 diabetes since
elevations in circulating proinsulin have been correlated with
age at diagnosis in individuals recently diagnosed with type 1
diabetes [10–12]. More specifically, we have assessed the
intracellular distribution of proinsulin and insulin in the islets
of individuals across three age ranges (<7 years, 7–12 years,
>13 years). This analysis was undertaken in a blinded manner
and the results then correlated with the profile of infiltrating
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immune cells in the islets of these same individuals. We have
also examined whether the circulating proinsulin:C-peptide
ratio measured in individuals with longer-standing type 1
diabetes and diagnosed across these same age ranges mirrors
the histological changes seen in the pancreas.
Methods
Pancreas samples for histopathological analysis
Pancreatic samples for study of immune cell infiltration were
described previously [8, 13] and details are given in electronic
supplementary material (ESM) Tables 1–3. Pancreatic samples
for study of proinsulin and insulin co-localisation were obtain-
ed from within the Exeter Archival Diabetes Biobank (EADB)
or the nPOD collection. With one exception, patients with
recent-onset type 1 diabetes in whom the localisation of proin-
sulin and insulin were studied had been diagnosed under
20 years of age (median 10.5 years, IQR 6.25–18.00 years).
A total of 19 patients with recent-onset (<2 years’ duration)
type 1 diabetes (ESM Tables 1 and 4) and 13 with longer-
duration (>5 years) disease were studied (ESM Tables 3 and
5) with full ethics approval (West of Scotland Research Ethics
Committee, reference: 15/WS/0258).
Staining of pancreatic samples
Immunostaining for insulin and proinsulin Pancreas sections
were immunostained for insulin and proinsulin using standard
immunofluorescent protocols. Staining was achieved with
validated antibodies that were highly selective for proinsulin
or mature insulin (ESM Table 6). Insulin-containing islets
(ICIs, n = 488) were studied across the 32 samples to establish
the co-localisation profiles. The sections were imaged via a
Leica DMi8 confocal microscope (Leica Microsystems [UK],
Milton Keynes, UK) and the distribution of proinsulin and
insulin examined in multiple islets using ImageJ (JACoP
plugin [14]; ImageJ, Bethesda, MD, USA). For analysis of
proinsulin:insulin localisation profiles in the islets of each
individual, images were analysed in a blinded manner among
individuals across the age ranges studied and samples were
selected arbitrarily in random order for analysis. The Manders
overlap coefficient (MOC) is the method of choice for estab-
lishing the extent of co-localisation of two proteins and was
calculated as an index of the extent of co-localisation of proin-
sulin with insulin [15].
Insulitis profiling Sections from each case were also immuno-
stained to detect CD4+, CD8+ and CD20+ cells using validated
antibodies, as described previously [8, 9]. Primary antibodies
are listed in ESM Table 6 and the immunohistochemical anal-
ysis was performed using Agilent/DAKO Envision reagents
(Agilent Technologies, Cheadle, Cheshire, UK) or Alexafluor
fluorophores (ThermoFisher, Loughborough, UK) with or
without the Tyramide SuperBoost (ThermoFisher) protocol.
Immunophenotyping was achieved as described previously
[8].
C-peptide, proinsulin and antibody measurement
in living individuals with long-duration disease
We examined 171 individuals with long-duration type 1
diabetes (>5 years) to assess their serum C-peptide, proinsulin
and proinsulin:C-peptide ratio. We recruited these participants
as part of the Type 1 diabetes, Immunology, Genetics and
endogenous Insulin production (TIGI) study, designed to
study associations of persistent C-peptide in type 1 diabetes,
and their clinical details are given in ESM Table 7. All partic-
ipants were diagnosed under 30 years, had a clinical diagnosis
of type 1 diabetes and were insulin treated from diagnosis.
Patients were included if their original diagnosis was made
at ages <7 years (n = 87) or ≥13 years (n = 84). We measured
stimulated serum proinsulin and C-peptide 90 min after a
mixed-meal tolerance test. We compared proinsulin levels
and proinsulin:C-peptide ratio in people with long-duration
type 1 diabetes with routine clinical samples from 39 people
without diabetes (age range 3–25 years). All participants
provided informed consent and the National Research Ethics
Service Committee South West approved the TIGI study (13/
SW/0312).
Biochemical analyses
Serum C-peptide was analysed using a direct electroche-
miluminescence immunoassay on the 602 module of the
COBAS 8000 platform (Roche Diagnostics, Mannheim,
Germany). The limit of detection was 3.3 pmol/l and intra
assay CV <4.7%. Proinsulin was measured using the TECO
Medical Intact Proinsulin ELISA kit (TECO, Sissach,
Switzerland) on the Dynex DS2 analyser (Dynex
Technologies, Chantilly, VA, USA). Limit of detection was
0.3 pmol/l; intra assay precision <7.5% (full details are provid-
ed in the ESM Validation Method). C-peptide and proinsulin
results below the limit of the assay were recorded as 2.9 pmol/l
and 0.29 pmol/l, respectively. Proinsulin:C-peptide ratio was
calculated only for those who had at least one detectable
value. The assumption that the undetectable analyte (most
commonly C-peptide) was just below the lower limit of assay
detection provided a conservative estimate of proinsulin:C-
peptide ratio.
Statistical analysis
The distribution of proinsulin and insulin in the pancreatic
samples from the different age groups at diagnosis was
Diabetologia (2020) 63:1258–12671260
compared using the Kolmogorov–Smirnov test. In samples
from living individuals, differences in C-peptide and
proinsulin:C-peptide ratio between subgroups were compared
using theMann–WhitneyU test. Data are presented in dot plot
format showing individual values with median and interquar-
tile ranges. Groups were considered statistically different
where the p value was <0.05.
Results
Examination of proinsulin distribution in the islets
of children diagnosed with type 1 diabetes
at different ages
When analysed in a blinded manner, two strikingly different
patterns of proinsulin immunostaining were seen in the
pancreases of children and young people recently diagnosed
with type 1 diabetes. In one group, proinsulin was predomi-
nantly distributed within a perinuclear compartment that was
largely devoid of insulin immunostaining, whereas mature
insulin was localised more widely within the cytoplasm (Fig.
1a). Accordingly, the median MOC was <0.5. In a second
group, the immunostaining pattern was strikingly different in
that proinsulin and insulin were unexpectedly co-localised
throughout the cytoplasm of the beta cells (Fig. 1b). This
was reflected in a median MOC for co-localisation of the
two antigens of >0.5.
Examination of the demographic features of the people falling
within the histologically distinct groups revealed that the children
in whom most ICIs displayed high proinsulin–insulin co-
localisation (MOC >0.5) were in the younger age group (under
13 years). More specifically, all five individuals diagnosed at
<7 years had high proinsulin–insulin co-localisation (MOC:
median 0.794, IQR 0.625–0.913) whereas six of seven individ-
uals diagnosed ≥13 years had low proinsulin–insulin co-
localisation (MOC: median 0.175, IQR 0.10–0.35; p < 0.0001)
(Fig. 2). This age distribution is strongly reminiscent of the age
profiles defining the two immune cell phenotypes reported previ-
ously in the inflamed islets of young people [8]. Hence, in chil-
dren aged <7 years or ≥13 years at diagnosis, there was a strong
correlation between the insulitis profiles defined previously as
‘CD20Hi’ or ‘CD20Lo’ [8] and the patterns of proinsulin immu-
nostaining (Fig. 2). Children diagnosed at <7 years and designat-
ed as ‘CD20Hi’ displayed unexpectedly high levels of
proinsulin–insulin co-localisation. By contrast, those diagnosed
≥13 years (‘CD20Lo’) had minimal proinsulin:insulin co-
localisation in most islets (Fig. 2). Study of the proinsulin–
insulin profiles seen in individuals of equivalent ages (either
<7 years or≥13 years) who did not have type 1 diabetes, revealed
that very few islets were present in which proinsulin co-localised
with insulin (Fig. 2).
In practice, among those diagnosed at ≥13 years the pattern of
proinsulin distribution was more complex in that two distinct
subpopulations of residual ICIs were usually present (Figs 2
and 3). As explained above, proinsulin and insulin were confined
to separate intracellular compartments in the majority of islets
while co-localisation of the antigens was seen in a small number
of islets in each case. Thus, with only one exception (Sc57) the
presence of these two clearly separable subpopulations of islets
was characteristic of individuals diagnosed at the older ages in
the pancreas sections studied (Fig. 3).
Individuals in the intermediate age group
at diagnosis (7–12 years) have one or other
of the histological phenotypes seen in those
diagnosed <7 or ≥13 years
A question arising from these observations is whether the
correlation between immune phenotype and proinsulin distri-
bution seen in children diagnosed at <7 years vs those diag-
nosed ≥13 years was retained within the intermediate age
group (i.e. among those diagnosed at 7–12 years). We found
that the proinsulin distribution in the ICIs of children aged 7–
12 years at diagnosis with a CD20Hi immune profile replicat-
ed those diagnosed at <7 years (Figs 2 and 3). By contrast, the
pattern seen in children who had a CD20Lo immune profile
replicated those diagnosed at ≥13 years (Figs 2 and 3). This
segregation of the ‘CD20’ and proinsulin–insulin co-
localisation phenotypes (Fig. 3b) supports the conclusion that
childhood-onset type 1 diabetes comprises distinct endotypes.
a b
Fig. 1 Fluorescence micrographs showing (a) Islet in which proinsulin
and insulin are segregated. Enlarged region (dotted square in upper panel)
is shown in the lower panel. (b) Islet with aberrant proinsulin processing.
Enlarged region (dotted square in upper) is shown in lower panel. Green,
insulin; red, proinsulin; yellow, co-localisation of the antigens. Scale bar,
20 μm
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Proinsulin–insulin co-localisation phenotypes
in pancreases from individuals with long-term type 1
diabetes diagnosed at <7 or ≥13 years
Immunohistological studies in longer-term type 1 diabe-
tes (>5 years’ duration) were also undertaken but were
inevitably limited by the fact that many fewer residual
ICIs are present at the time of death than at disease
onset [6]. This is particularly true among those diag-
nosed at <7 years, where only 17% of individuals retain
any ICIs (vs 48% in those diagnosed at ≥13 years; ESM
Fig. 1). Therefore, for studies in longer duration patients
we used pancreas samples from both the EADB and
nPOD collections (ESM Tables 3 and 5).
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Fig. 3 (a) Dot plots showing the distribution of the mean MOC for islets
within each individual. Individuals were grouped by age at diagnosis
(with each age range separated by blue lines) and according to their
immune cell profiles (whether CD2Hi or CD20Lo; using the grey dashed
line). (b) Scatterplot of the number of CD20+ cells per ICI arranged by
median, and plotted against the mean MOC for islets in each case.
Different age ranges indicated by the fill colour: red, <7 years; purple,
7–12 years; blue, ≥13 years
Fig. 2 Dot plot showing distribution of the MOC (a measure of proinsu-
lin–insulin co-localisation) in individual islets from pancreas samples
obtained within 2 years of diagnosis of type 1 diabetes for individuals
with disease onset at <7 years, 7–12 years and ≥13 years. Individuals in
each age group were separated into CD20Hi (red) and CD20Lo (blue)
subgroups, respectively. Data from control individuals without diabetes
are presented as grey circles for those aged <7 years (far left) or ≥13 years
(far right). Black horizontal bars represent median values for each group
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The pattern of proinsulin–insulin co-localisation found in
those with longer duration of disease varied from that seen
close to diagnosis, with a reduction in the proportion of islets
having high proinsulin–insulin co-localisation (Fig. 4). In
those diagnosed at ≥13 years, a higher proportion of ICIs
persisted (ESM Fig. 1) and proinsulin–insulin co-localisation
was minimal (Fig. 4).
Differences in serum C-peptide and proinsulin
in individuals with long-term type 1 diabetes
diagnosed at <7 or ≥13 years
In order to discover whether the histological differences in the
pancreas correlate with relevant clinical variables, circulating
proinsulin and C-peptide concentrations were measured in
individuals with longer-term type 1 diabetes (≥5 years) within
the two distinct age groups (diagnosed at <7 years or ≥13 years
of age; ESM Table 7). The patients who were diagnosed at
<7 years had much lower stimulated C-peptide levels than
patients diagnosed at ≥13 years (Fig. 5; median <3 pmol/l,
IQR <3 to <3 vs 34.5 pmol/l, IQR <3–151; p < 0.0001).
Approximately 70% had detectable proinsulin (72% of the
<7 years group and 67% of the ≥13 years group, p = 0.4) with
a median proinsulin level of 0.45 pmol/l (IQR <0.3–0.8) in the
<7 years group vs 0.5 pmol/l (IQR <0.3–1.6) (p = 0.3) in the
>13 years group (ESM Table 7). 62% had detectable proinsu-
lin even in the absence of detectable C-peptide. Strikingly, the
median proinsulin:C-peptide ratio was significantly increased
in those diagnosed at <7 years compared with individuals
diagnosed at ≥13 years (Fig. 6) (0.18, IQR 0.10–0.31 vs
0.01, IQR 0.01–0.10; p < 0.0001) and control individuals
without diabetes (0.003, IQR 0.002–0.005; p < 0.0001).
Absolute proinsulin values are shown in ESM Fig. 2. These
data suggest that clear phenotypic differences can be detected
in the blood of the two type 1 diabetes groups defined by age
of diagnosis.
Discussion
Our results strongly suggest that type 1 diabetes exists as
distinct conditions that segregate according to age at diagnosis
and are distinguishable histologically. They can be defined by
the profile of infiltrating immune cells in inflamed islets and
by the extent to which proinsulin and insulin are co-localised
within beta cells. We propose that these may represent disease
endotypes and suggest that they are defined as type 1 diabetes
endotype 1 (T1DE1) and type 1 diabetes endotype 2 (T1DE2).
Fig. 6 Dot plot showing the proinsulin:C-peptide ratio in individuals with
at least one detectable value for those diagnosed with type 1 diabetes
<7 years (n = 62; red) or ≥13 years (n = 70; blue) and for control individ-
uals (n = 39; grey). Black bars represent median values for each group
Fig. 5 Dot plot showing 90 min stimulated C-peptide values in individ-
uals diagnosed at <7 years (n = 87; red) or ≥13 years (n = 84; blue). Black
bars represent median values for each group
Fig. 4 Dot plot showing distribution of the mean MOC for islets in
pancreas samples from individuals with long duration of type 1 diabetes
(≥5 years’ duration) and originally diagnosed at <7 years (n = 3; red) and
≥13 years (n = 10; blue). Black bars represent median values for each
group
Diabetologia (2020) 63:1258–1267 1263
In advancing this proposal, we do not intend to imply that a
simple dichotomy will ultimately be sufficient to account for
the entire heterogeneity seen in people developing type 1
diabetes. Rather, it is probable that additional endotypes will
be defined as further variables are considered. Nevertheless,
the present results suggest that future therapeutic trials in type
1 diabetes should be designed to take account of the important
aetiopathological differences that are now being revealed.
This might be achieved most readily by noting the age at
diagnosis. Specifically, we propose that children diagnosed
in the earliest years of life may require different immunother-
apeutic options vs those who are older at onset.
To verify the existence of endotypes of type 1 diabetes, we
focused on the subcellular distribution of proinsulin and
mature insulin in the residual beta cells present in individuals
diagnosed with type 1 diabetes at different ages and related
these to previously described immune phenotypes [8]. This
revealed that, among children developing the condition before
the age of 7 years (CD20Hi phenotype; T1DE1) there is
disruption of insulin processing. In almost all islets (and with-
in all residual beta cells in those islets), significant quantities
of the newly synthesised prohormone become co-localised
with mature insulin. This situation contrasts markedly with
that found in control individuals of equivalent age and in
young people developing diabetes after the age of 12 years
(T1DE2), where proinsulin was preferentially retained within
a perinuclear compartment in most islets and was not co-
localised with mature insulin. Thus, we have been able to
define disease endotypes that segregate according to age at
diagnosis and can be differentiated histologically by alter-
ations in proinsulin processing and immune phenotype.
Measurements of serum proinsulin reflect
the histological appearance
Importantly, we have also been able to correlate new clinical
data with the histological findings (albeit in different individ-
uals) to verify our conclusions. Notably, we found that
although absolute stimulated C-peptide levels were reduced
in the youngest individuals (diagnosed at age <7 years), the
ratio of serum proinsulin:C-peptide was elevated in these indi-
viduals since proinsulin levels in the circulation were main-
tained (ESM Fig. 2). This was true even when the individuals
were studied more than 5 years after diagnosis. As such, these
data are fully consistent with reports that circulating proinsulin
levels are highest in children diagnosed below the age of
10 years who are studied at, or soon after, diagnosis [10,
11]. We also show that similarly aged control individuals have
a much lower proinsulin:C-peptide ratio (Fig. 6), demonstrat-
ing that this is not an effect of age alone. Together, these data
imply that, when considered alongside age at diagnosis,
measurement of the ratio of proinsulin to C-peptide may
represent a convenient biomarker to distinguish the endotypes
defined here.
Our data fit with the emerging literature that detectable
proinsulin, even in the absence of detectable C-peptide, can
occur in type 1 diabetes of long duration [16, 17]. Steenkamp
et al [17] described 16% of patients with detectable proinsulin
compared with Sims et al [16] who reported 90% with detect-
able proinsulin. Our data fit most closely with the results of
Sims and colleagues [16]; however, differences in the analyt-
ical sensitivity of assays and in the cohorts may explain the
difference between the studies [16, 17]. To aid comparison,
and to inform future clinical studies of proinsulin, we have
included the detailed method validation we undertook prior
to using the assay in this study (see ESM Validation Method).
Our data are also consistent with other evidence implying that
the prohormone convertases and carboxypeptidase E involved
in proinsulin cleavage may become downregulated in type 1
diabetes [18, 19]. The consequence of such changes is that,
rather than being processed fully to yield mature insulin on
emergence from the Golgi apparatus in nascent secretory
granules, significant amounts of proinsulin persist. This accu-
mulates with insulin and is released into the circulation upon
granule exocytosis, leading to a measurable rise in the circu-
lating proinsulin:C-peptide ratio.
The patterns of proinsulin processing seen in children
diagnosed in the intermediate age group (7–12 years)
support the existence of disease endotypes
The present conclusion that endotypes of type 1 diabetes exist
has arisen from studies of individuals diagnosed with type 1
diabetes at the two extremes of our chosen age ranges.
Therefore, it was important to also examine the pancreases
of children newly diagnosed with type 1 diabetes between
the ages of 7–12 years. These provided further important
evidence for independent pathological processes since quan-
tification of the extent of proinsulin–insulin co-localisation
allowed this group to be divided into two separate popula-
tions. One of these mirrored the features found in the <7 years
group while the other had a profile equivalent to that found in
those in the ≥13 years group. Importantly, despite being
analysed in a blinded manner, all individuals segregated with
their previously designated immune cell phenotypes (whether
CD20Hi or CD20Lo; Figs 2 and 3). Thus, we were able to
establish that the pathological features seen in the pancreases
of children diagnosed within the mid-range of ages (between
7–12 years) did not form a continuum but, rather, they segre-
gated with the proposed endotypes.
These observations suggest that the aetiopathology of type
1 diabetes occurs by different pathways in very young chil-
dren compared with those who are older at diagnosis. The first
of these (T1DE1) involves a highly aggressive, hyperimmune
attack in which most islets are inflamed and aberrant
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proinsulin processing occurs. This leads to the co-secretion of
both unprocessed and mature insulin, such that the circulating
ratio of proinsulin:C-peptide is unusually high. By contrast, a
different endotype (T1DE2) is characterised by a reduced
intensity of islet autoimmunity, the persistence of higher
proportions of ICIs (each with greater numbers of beta cells)
and a lower circulating proinsulin:C-peptide ratio.
Very recent data imply that children diagnosed with type 1
diabetes at <7 years or ≥13 years may display differences in
genetic predisposition [20, 21]; a finding that is fully consis-
tent with our endotype hypothesis. It cannot be excluded,
however, that the immune cell and proinsulin processing
profiles could be influenced by other physiological changes
occurring during development (e.g. the onset of puberty) rath-
er than solely by a differing genetic architecture. In either case,
it is abundantly clear that very different outcomes derive from
the autoimmune process in children diagnosed with type 1
diabetes <7 years vs those >13 years.
Individuals with T1DE2 have two populations of islets
Clinical studies have shown that a significant proportion of
people with type 1 diabetes continue to secrete insulin for
many years beyond diagnosis [22–24], although this is rare
in children diagnosed <7 years (Fig. 5). In support of these
findings, we have recently discovered that the rate of C-
peptide decline seen early in the disease course is markedly
attenuated, and effectively ceases, from about 7 years after
onset [25]. Thus, even people with very long-standing disease
may retain ICIs which secrete small amounts of insulin [6, 26,
27]. In view of this, we explored whether the aberrant pattern
of proinsulin:insulin co-localisation seen at diagnosis is main-
tained in residual ICIs over time. Recent data from others [19],
as well as our current histological results, support this. We also
noted that the proportion of islets in which proinsulin and
insulin were co-localised was reduced in individuals with
longer duration of disease, even among those who had been
diagnosed initially before the age of 7 years (Fig. 4). This
implies that the population of ICIs that persists in the longer
term mainly comprises those islets that are least prone to the
abnormalities of proinsulin processing reported here, and are
spared preferentially during the autoimmune attack.
Alternatively, it is also possible that individuals with more
complete proinsulin processing at baseline have improved
survival of beta cells overall, leading to higher numbers of
residual insulin positive islets over time. Further studies will
be required to resolve these possibilities.
Limitations
We are aware that the current study has certain limitations; not
least that the number of samples examined for proinsulin
processing in each age group is small. However, we would
emphasise that such studies are limited by the availability of
suitably fixed and processed pancreas samples from people
with recent-onset disease. Indeed, using a cut-off of 2 years
post diagnosis and childhood onset of disease, very few suit-
able samples are available worldwide [6] and we have studied
the majority of these; which is a clear strength. Moreover, the
differences in the immune cell and proinsulin processing
profiles between the age groups is stark and provides compel-
ling support for the existence of disease endotypes.
A second potential weakness is that many of the individ-
uals with type 1 diabetes died in ketoacidosis (ESM Table 1),
meaning that their islets were subject to metabolic stress.
However, the fact that all individuals within the intermediate
age range (7–12 years) died in diabetic ketoacidosis but their
proinsulin profiles segregated precisely with their islet
immune phenotype (Fig. 2) implies that these differences were
unlikely to have been caused directly by the presence of
diabetic ketoacidosis.
Third, we have not studied proinsulin processing in the
pancreases of older adults at the onset of type 1 diabetes
[28]. We cannot, therefore, extrapolate beyond the childhood
disease. This is important since a recent histopathological
study has reported differences in islet cell proinsulin distribu-
tion in correlation with islet cell autoantibody status in adults
who had not progressed to diabetes [29] and heterogeneity in
adult-onset autoimmune diabetes has been reported [30].
Despite this, and in accord with our observations in people
diagnosed in their teenage years, proinsulin was still clearly
distinguishable within the perinuclear region of an islet of an
adult with newly diagnosed type 1 diabetes who had under-
gone pancreatic biopsy [29]. We should also note that,
although we have occasionally seen individual beta cells in
control islets that immunostain very strongly for proinsulin in
the cytoplasm, the frequency at which these appear is much
lower than that seen in the islets of children with type 1 diabe-
tes (Fig. 2).
Implications of the study
Importantly, age-dependent differences in both rates of C-
peptide decline and drug responses have been seen in several
clinical trials in type 1 diabetes [2, 31–37] and this highlights
the possibility of stratification according to age at diagnosis.
Disease endotypes have also been inferred in separate studies
of the temporal sequence of islet autoantibody seroconversion
in The Environmental Determinants of Diabetes in the Young
(TEDDY) study. In particular, a recent cluster analysis of
TEDDY data implies that children who develop combinations
of autoantibodies to insulin and islet antigen 2 (IA2) (with or
without GAD65) within the first 2 years of life are likely to
progress to diabetes within 5 years (i.e. before the age of
7 years) [38]. Thus, it seems likely that these may correspond
to children with the T1DE1 endotype defined here. Future
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therapeutic strategies will need to take account of such differ-
ences if they are to be effective.
Acknowledgements Parts of the study were presented in abstract form to
the JDRF nPOD Annual Meeting Fort Lauderdale FL, February 2018;
54th EASDCongress, Berlin, September 2018; the International Diabetes
Society, London, October 2018 and the Diabetes UKAnnual Professional
Conference, Manchester, March 2019.
Data availability The datasets generated during and/or analysed during
the current study are available from the corresponding authors on reason-
able request.
Funding We are grateful to Diabetes UK for financial support via project
grant 16/0005480 (to NGM and SJR) and to JDRF for a Career
Development Award to SJR (5-CDA-2014-221-A-N). The research was
performed with the support of the Network for Pancreatic Organ Donors
with Diabetes (nPOD), a collaborative type 1 diabetes research project
sponsored by JDRF. Organ Procurement Organizations (OPO) partnering
with nPOD to provide research resources are listed at http://www.
jdrfnpod.org//for-partners/npod-partners/. ATH and BMS are supported
by the NIHR Exeter Clinical Research Facility. BMS is supported as part
of the MRC MASTERMIND consortium. TJM is funded by an NIHR
clinical senior lecturer fellowship. ATH is supported by aWellcome Trust
Senior Investigator Award (WT098395/Z/12/Z) and an NIHR Senior
Investigator award. RAO is supported by a Diabetes UK Harry Keen
Fellowship.
Authors’ relationships and activities The authors declare that there are no
relationships or activities that might bias, or be perceived to bias, their
work.
Contribution statement PL designed the study, collected and analysed
data, prepared figures, undertook literature searches and edited the
manuscript. CZ, RO and TJM collected data, undertook literature
searches and edited the manuscript. BMS analysed data, prepared
figures and edited the manuscript. All authors approved the final
version of the manuscript. ATH, SJR and NGM were principal
investigators supervising the study; they analysed and interpreted data,
wrote the manuscript and are the guarantors of this work.
Appendix
Members of the TIGI study team: Bart O. Roep (Leiden
University Medical Center, Leiden, Netherlands &
Department of Diabetes Immunology, Diabetes &
Metabolism Research Institute, Beckman Research Institute,
City of Hope, CA, USA); Timothy I. Tree (Department of
Immunobiology, Faculty of Life Sciences and Medicine,
King’s College London, London, UK); Kashyap Patel, Suzy
Hammersley, Robert Bolt and Anita V. Hill (all NIHR CRF,
University of Exeter Medical School, Exeter, UK).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in
the article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Skyler JS, Bakris GL, Bonifacio E et al (2017) Differentiation of
diabetes by pathophysiology, natural history, and prognosis.
Diabetes 66(2):241–255. https://doi.org/10.2337/db16-0806
2. DiMeglio LA, Evans-Molina C, Oram RA (2018) Type 1 diabetes.
Lancet 391(10138):2449–2462. https://doi.org/10.1016/S0140-
6736(18)31320-5
3. Atkinson M, Roep BO, Posgai A, Wheeler DCS, Peakman M
(2018) The challenge of modulating β-cell autoimmunity in type
1 diabetes. Lancet Diabetes Endocrinol 7:52–64
4. Herold KC, Bundy BN, Long SA et al (2019) An anti-CD3 anti-
body, teplizumab, in relatives at risk for type 1 diabetes. N Engl J
Med 381:603–613
5. Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS
(1986) The histopathology of the pancreas in type 1 (insulin-
dependent) diabetes mellitus: a 25-year review of deaths in patients
under 20 years of age in the United Kingdom. Diabetologia 29(5):
267–274
6. Morgan NG, Richardson SJ (2018) Fifty years of pancreatic islet
pathology in human type 1 diabetes: insights gained and progress
made. Diabetologia 61:2499–2506
7. Battaglia M, Ahmed S, Anderson MS et al (2020) Introducing the
endotype concept to address the challenge of disease heterogeneity
in type 1 diabetes. Diabetes Care 43:5–12
8. Leete P, Willcox A, Krogvold L et al (2016) Differential insulitic
profiles determine the extent of beta cell destruction and the age at
onset of type 1 diabetes. Diabetes 65:1362–1369
9. Arif S, Leete P, Nguyen V et al (2014) Blood and islet phenotypes
indicate immunological heterogeneity in type 1 diabetes. Diabetes
63(11):3835–3845. https://doi.org/10.2337/db14-0365
10. Sims EK, Chaudhry Z, Watkins R et al (2016) Elevations in the
fasting serum proinsulin-to-C-peptide ratio precede the onset of
type 1 diabetes. Diabetes Care 39(9):1519–1526. https://doi.org/
10.2337/dc15-2849
11. Watkins RA, Evans-Molina C, Terrell JK et al (2016) Proinsulin
and heat shock protein 90 as biomarkers of beta-cell stress in the
early period after onset of type 1 diabetes. Transl Res 168:96–106
e101. https://doi.org/10.1016/j.trsl.2015.08.010
12. Roder ME, Knip M, Hartling SG, Karjalainen J, Akerblom HK,
Binder C (1994) Disproportionately elevated proinsulin levels
precede the onset of insulin-dependent diabetes mellitus in siblings
with low first phase insulin responses. The Childhood Diabetes in
Finland Study Group. J Clin Endocrinol Metab 79(6):1570–1575.
https://doi.org/10.1210/jcem.79.6.7989457
13. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG
(2009) Analysis of islet inflammation in human type 1 diabetes.
Clin Exp Immunol 155(2):173–181
14. Bolte S, Cordelières FP (2006) A guided tour into subcellular
colocalization analysis in light microscopy. J Microsc 224(3):
213–232. https://doi.org/10.1111/j.1365-2818.2006.01706.x
15. Manders EMM, Verbeek FJ, Aten JA (1993) Measurement of co-
localization of objects in dual-colour confocal images. J Microsc
169(3):375–382. https://doi.org/10.1111/j.1365-2818.1993.
tb03313.x
Diabetologia (2020) 63:1258–12671266
16. Sims EK, Bahnson HT, Nyalwidhe J et al (2019) Proinsulin secre-
tion is a persistent feature of type 1 diabetes. Diabetes Care 42(2):
258–264. https://doi.org/10.2337/dc17-2625
17. SteenkampDW, Cacicedo JM, Sahin-Efe A, Sullivan C, Sternthal E
(2017) Preserved proinsulin secretion in long-standing type 1 diabe-
tes. Endocr Pract 23(12):1387–1393. https://doi.org/10.4158/ep-
2017-0009
18. Wasserfall C, Nick HS, Campbell-Thompson M et al (2017)
Persistence of pancreatic insulin mRNA expression and proinsulin
protein in type 1 diabetes pancreata. Cell Metab 26(3):568–575
e563. https://doi.org/10.1016/j.cmet.2017.08.013
19. Sims EK, Syed F, Nyalwidhe J et al (2019) Abnormalities in proin-
sulin processing in islets from individuals with longstanding T1D.
Transl Res 213:90–99
20. Inshaw JRJ, Cutler AJ, Crouch DJM, Wicker LS, Todd JA (2019)
Genetic variants predisposing most strongly to type 1 diabetes diag-
nosed under age 7 years lie near candidate genes that function in the
immune system and in pancreatic β-cells. Diabetes Care 43:169–
177
21. Redondo MJ, Concannon P (2020) Genetics of type 1 diabetes
comes of age. Diabetes Care 43(1):16–18. https://doi.org/10.2337/
dci19-0049
22. Oram RA, Jones AG, Besser RE et al (2014) The majority of
patients with long-duration type 1 diabetes are insulin
microsecretors and have functioning beta cells. Diabetologia
57(1):187–191. https://doi.org/10.1007/s00125-013-3067-x
23. Davis AK, DuBose SN, Haller MJ et al (2015) Prevalence of detect-
able C-peptide according to age at diagnosis and duration of type 1
diabetes. Diabetes Care 38(3):476–481. https://doi.org/10.2337/
dc14-1952
24. Wang L, Lovejoy NF, Faustman DL (2012) Persistence of
prolonged C-peptide production in type 1 diabetes as measured
with an ultrasensitive C-peptide assay. Diabetes Care 35(3):465–
470. https://doi.org/10.2337/dc11-1236
25. Shields BM, McDonald TJ, Oram R et al (2018) C-peptide decline
in type 1 diabetes has two phases: an initial exponential fall and a
subsequent stable phase. Diabetes Care 41:1486–1492. https://doi.
org/10.2337/dc18-0465
26. Keenan HA, Sun JK, Levine J et al (2010) Residual insulin produc-
tion and pancreatic beta-cell turnover after 50 years of diabetes:
Joslin Medalist Study. Diabetes 59(11):2846–2853. https://doi.
org/10.2337/db10-0676
27. Battaglia M, Atkinson MA (2015) The streetlight effect in type 1
diabetes. Diabetes 64(4):1081–1090. https://doi.org/10.2337/db14-
1208
28. Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA,
Hattersley AT (2018) Frequency and phenotype of type 1 diabetes
in the first six decades of life: a cross-sectional, genetically stratified
survival analysis from UK Biobank. Lancet Diabetes Endocrinol
6(2):122–129. https://doi.org/10.1016/S2213-8587(17)30362-5
29. Rodriguez-Calvo T, Zapardiel-Gonzalo J, Amirian N et al (2017)
Increase in pancreatic proinsulin and preservation of beta-cell mass
in autoantibody-positive donors prior to type 1 diabetes onset.
Diabetes 66(5):1334–1345. https://doi.org/10.2337/db16-1343
30. Buzzetti R, Zampetti S, Maddaloni E (2017) Adult-onset autoim-
mune diabetes: current knowledge and implications for manage-
ment. Nat Rev Endocrinol 13:674. https://doi.org/10.1038/nrendo.
2017.99
31. Wherrett DK, Chiang JL, Delamater AM et al (2015) Defining
pathways for development of disease-modifying therapies in chil-
drenwith type 1 diabetes: a consensus report. Diabetes Care 38(10):
1975–1985. https://doi.org/10.2337/dc15-1429
32. Keymeulen B, Walter M, Mathieu C et al (2010) Four-year meta-
bolic outcome of a randomised controlled CD3-antibody trial in
recent-onset type 1 diabetic patients depends on their age and base-
line residual beta cell mass. Diabetologia 53(4):614–623
33. Hagopian W, Ferry RJ Jr, Sherry N et al (2013) Teplizumab
preserves C-peptide in recent-onset type 1 diabetes: two-year
results from the randomized, placebo-controlled Protege trial.
Diabetes 62(11):3901–3908. https://doi.org/10.2337/db13-0236
34. Rigby MR, DiMeglio LA, Rendell MS et al (2013) Targeting of
memory T cells with alefacept in new-onset type 1 diabetes
(T1DAL study): 12 month results of a randomised, double-blind,
placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 1(4):
284–294. https://doi.org/10.1016/S2213-8587(13)70111-6
35. RigbyMR, Harris KM, Pinckney A et al (2015) Alefacept provides
sustained clinical and immunological effects in new-onset type 1
diabetes patients. J Clin Invest 125(8):3285–3296. https://doi.org/
10.1172/JCI81722
36. Orban T, Bundy B, Becker DJ et al (2011) Co-stimulation modula-
tion with abatacept in patients with recent-onset type 1 diabetes: a
randomised, double-blind, placebo-controlled trial. Lancet
378(9789):412–419. https://doi.org/10.1016/S0140-6736(11)
60886-6
37. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al (2009)
Rituximab, B-lymphocyte depletion, and preservation of beta-cell
function. N Engl J Med 361(22):2143–2152. https://doi.org/10.
1056/NEJMoa0904452
38. Krischer JP, Lynch KF, Lernmark A et al (2017) Genetic and envi-
ronmental interactions modify the risk of diabetes-related autoim-
munity by 6 years of age: the TEDDY Study. Diabetes Care 40(9):
1194–1202. https://doi.org/10.2337/dc17-0238
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Diabetologia (2020) 63:1258–1267 1267
